相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab and daily temozolomide for recurrent glioblastoma
Annick Desjardins et al.
CANCER (2012)
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na⟨ve, recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Prospective, high-throughput molecular profiling of human gliomas
Andrew S. Chi et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
CANCER (2011)
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
David Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
C. Lu-Emerson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma
Ufuk Abacioglu et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
John M. L. Ebos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The paradoxical effect of bevacizumab in the therapy of malignant gliomas
Eric M. Thompson et al.
NEUROLOGY (2011)
Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
Jennifer C. Kesselheim et al.
ONCOLOGIST (2011)
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
J. J. C. Verhoeff et al.
ANNALS OF ONCOLOGY (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
Roy G. Torcuator et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
Richard M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
Doo-Sik Kong et al.
NEURO-ONCOLOGY (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma
A. Idbaih et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide
Qingyu Zhou et al.
CLINICAL CANCER RESEARCH (2008)
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
An Claes et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Susan M. Chang et al.
NEURO-ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lessons learned in the development of targeted therapy for malignant gliomas
Antonio M. P. Omuro et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
Jeffrey C. Lee et al.
PLOS MEDICINE (2006)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Salvage temozolomide for prior temozolomide responders
E Franceschi et al.
CANCER (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inhibition of angiogenesis by non-toxic doses of temozolomide
H Kurzen et al.
ANTI-CANCER DRUGS (2003)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
